Hepatitis Monthly

Published by: Kowsar

Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

Babak Sayad 1 , * , Fatemeh Norooznezhad 1 and Alireza Farokhi 1
Authors Information
1 Liver Diseases Research Center, Kermanshah University of Medical Sciences, Iran
Article information
  • Hepatitis Monthly: March 2017, 17 (3); e58720
  • Published Online: March 8, 2017
  • Article Type: Letter
  • Received: February 13, 2017
  • Accepted: March 1, 2017
  • DOI: 10.5812/hepatmon.46588

To Cite: Sayad B, Norooznezhad F, Farokhi A. Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”, Hepat Mon. 2017 ; 17(3):e58720. doi: 10.5812/hepatmon.46588.

Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon. 2016; 17(1)[DOI]
  • 2. American Association for the Study of Liver Diseases . Recommendations for Testing, Managing, and Treating Hepatitis C. 2016;
  • 3. E. A. S. L. . EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017; 66(1): 153-94[DOI]
  • 4. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015; 63(1): 20-9[DOI][PubMed]
  • 5. Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother. 2015; 49(6): 674-87[DOI][PubMed]
  • 6. Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D, et al. Antiretroviral use in the Cease cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2016; 3(2)[DOI]
  • 7. Macias J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med. 2016; [DOI][PubMed]
  • 8. Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, et al. A Review of Daclatasvir Drug-Drug Interactions. Adv Ther. 2016; 33(11): 1867-84[DOI][PubMed]
  • 9. Smolders EJ, Colbers EP, de Kanter CT, Velthoven-Graafland K, Drenth JP, Burger DM. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat. J Antimicrob Chemother. 2017; 72(2): 486-9[DOI][PubMed]
  • 10. National protecol for evaluation of patients with HIV/AIDS and antiretroviral treatment in adolescent and adults. 2014;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments